ABSTRACT
Since the seminal work of Kohler and Milstein (1) ushered in the monoclonal antibody (MAb) era 20 years ago, developments in MAb technology have led to the identification of numerous new human tumor-associated antigens (TAAs). Monoclonal antibody technology has had a significant impact on our understanding of basic cancer biology and has also become an important component in the evolution of the immunodiagnosis and immunotherapy of cancer. The unique properties of MAbs including their antigenic specificity, internalization by the cell, and their clearance and excretion from the body have been capitalized upon in both preclinical and clinical studies of cancer.
